Key Insights
The European DNA testing market, valued at €6.17 billion in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 10.55% from 2025 to 2033. This expansion is driven by several key factors. Increasing prevalence of genetic disorders, coupled with rising awareness of personalized medicine and preventative healthcare, fuels demand for DNA testing across various segments. Advancements in molecular testing technologies, offering higher accuracy, faster turnaround times, and reduced costs, are further propelling market growth. Furthermore, the expanding role of genetic information in disease diagnosis, treatment selection, and risk assessment is creating significant opportunities for market players. The strong regulatory framework within Europe, promoting ethical and responsible DNA testing practices, also contributes to market stability and growth. Significant investments in research and development by both established players and emerging biotech companies are fueling innovation within the sector, leading to the development of novel testing methodologies and applications. Key market segments such as carrier testing, prenatal testing, and cancer-related genetic testing are expected to witness particularly rapid growth during the forecast period.
Within the European market, Germany, France, the United Kingdom, and Italy represent the largest national markets, driven by factors such as advanced healthcare infrastructure, high healthcare expenditure, and a growing understanding of the benefits of genetic screening. However, significant growth potential exists in other European countries as awareness and accessibility to DNA testing increase. Competitive landscape analysis indicates a blend of large multinational corporations like Roche and Thermo Fisher Scientific alongside smaller, specialized companies focused on niche areas within genetic testing. This competitive dynamics fuels innovation and ensures a continuous improvement in the quality and affordability of DNA testing services. Challenges such as data privacy concerns, ethical implications, and the need for improved patient education remain, but are being actively addressed by industry stakeholders and regulators.
European DNA Testing Industry: A Comprehensive Market Report (2019-2033)
This in-depth report provides a comprehensive analysis of the European DNA testing industry, offering valuable insights for stakeholders, investors, and industry professionals. With a study period spanning 2019-2033, a base and estimated year of 2025, and a forecast period of 2025-2033, this report unveils the market's dynamic landscape, revealing growth trajectories, competitive dynamics, and future opportunities. The report covers a market valued at xx Million in 2025 and projects a xx Million valuation by 2033, representing a robust CAGR of xx%.
European DNA Testing Industry Market Dynamics & Concentration
The European DNA testing market exhibits a moderately concentrated landscape, with several multinational corporations holding significant market share. Key players such as Myriad Genetics Inc, Elitech Group, Luminex Corporation (Diasorin SPA), F Hoffmann-La Roche Ltd, Eurofins Scientific, 23andMe Inc, Abbott Laboratories, Blueprint Genetics Oy, Danaher Corporation, Qiagen, Illumina Inc, Centogene AG, and Thermo Fisher Scientific compete intensely, driving innovation and shaping market dynamics. Market share analysis reveals that the top 5 players collectively control approximately xx% of the market (2025 estimate), indicating moderate concentration. The historical period (2019-2024) witnessed xx M&A deals, primarily driven by strategic acquisitions aimed at expanding technological capabilities and geographic reach. Regulatory frameworks, particularly those concerning data privacy (GDPR) and ethical considerations around genetic information, significantly influence market operations. The industry also faces pressure from substitute technologies, including advanced diagnostic imaging techniques. End-user trends, shifting towards personalized medicine and proactive healthcare management, positively impact market growth.
- Market Concentration: Top 5 players hold approximately xx% market share (2025 estimate).
- M&A Activity: xx deals during 2019-2024.
- Regulatory Landscape: Stringent data privacy regulations (GDPR) and ethical guidelines.
- Substitute Technologies: Advanced diagnostic imaging.
- End-User Trends: Growing demand for personalized medicine and proactive healthcare.
European DNA Testing Industry Industry Trends & Analysis
The European DNA testing market is experiencing substantial growth, fueled by technological advancements, increased awareness of genetic diseases, and expanding applications across various healthcare segments. The market's CAGR from 2025 to 2033 is projected at xx%, driven by factors including the rising prevalence of chronic diseases, increasing adoption of preventative healthcare measures, and government initiatives promoting genetic testing. Technological disruptions, such as the development of next-generation sequencing (NGS) technologies and CRISPR-Cas9 gene editing, are reshaping the industry landscape. Consumer preferences are increasingly geared towards convenient, accurate, and affordable testing options. The competitive dynamics are characterized by intense rivalry, strategic partnerships, and a continuous drive for innovation. Market penetration for genetic testing varies across European countries, with higher adoption rates observed in nations with well-established healthcare infrastructure and favorable reimbursement policies. The market is further segmented by technology (cytogenetic, biochemical, molecular), disease (cancer, cystic fibrosis, etc.), and test type (carrier, diagnostic, prenatal, etc.).
Leading Markets & Segments in European DNA Testing Industry
The German market is currently the leading market within Europe due to factors including strong healthcare infrastructure, a high prevalence of certain genetic diseases, and significant investment in healthcare technologies. The United Kingdom shows strong potential for growth due to recent government initiatives.
By Type:
- Prenatal Testing: High growth due to increasing awareness of congenital disorders.
- Diagnostic Testing: Largest segment driven by the need for accurate diagnoses.
- Carrier Testing: Growing adoption rates among couples planning families.
By Disease:
- Cancer: Largest segment driven by high prevalence and the need for early detection.
- Cystic Fibrosis: Significant market driven by widespread screening programs.
- Other Diseases: Growth potential exists in other areas like Alzheimer's and Huntington's Disease.
By Technology:
- Molecular Testing: Dominant technology, fueled by advancements in NGS and PCR.
Key Drivers:
- Robust healthcare infrastructure in certain countries (Germany, UK).
- High prevalence of specific genetic diseases.
- Favorable government policies supporting genetic testing.
- Increased awareness of genetic disorders and their impact on health.
European DNA Testing Industry Product Developments
The European DNA testing industry is witnessing continuous product innovation, driven by advancements in sequencing technologies, bioinformatics, and data analytics. New products are characterized by increased accuracy, reduced costs, faster turnaround times, and expanded applications. For example, the integration of artificial intelligence (AI) is enhancing diagnostic accuracy and enabling personalized treatment strategies. Companies are focusing on developing user-friendly, at-home testing kits to improve accessibility and convenience. This trend is aimed at enhancing market fit and expanding reach beyond traditional clinical settings. The development of non-invasive prenatal testing (NIPT) is a significant advancement, improving safety and accuracy in detecting fetal chromosomal abnormalities.
Key Drivers of European DNA Testing Industry Growth
The European DNA testing industry is propelled by several key growth drivers:
- Technological Advancements: Next-generation sequencing (NGS) and CRISPR-Cas9 gene editing technologies are enhancing test accuracy and reducing costs.
- Increased Awareness: Rising public awareness of genetic diseases and the benefits of early detection is driving demand for testing.
- Favorable Regulatory Environment: Government initiatives promoting genetic testing and supporting research.
Challenges in the European DNA Testing Industry Market
The European DNA testing market faces several challenges:
- Regulatory Hurdles: Stringent data privacy regulations and ethical considerations around genetic information create complexities for companies.
- High Costs: The high cost of testing can limit accessibility, particularly in resource-constrained healthcare systems.
- Competitive Pressure: Intense competition among numerous established players and new entrants.
Emerging Opportunities in European DNA Testing Industry
Long-term growth opportunities abound in the European DNA testing market:
- Technological Breakthroughs: Continued advancements in NGS and other technologies offer opportunities for enhanced accuracy, efficiency, and cost reduction.
- Strategic Partnerships: Collaborations between testing companies, research institutions, and healthcare providers can expand access and adoption of testing.
- Market Expansion: Growth opportunities exist in underserved regions of Europe, particularly those with emerging healthcare infrastructure.
Leading Players in the European DNA Testing Industry Sector
- Myriad Genetics Inc
- Elitech Group
- Luminex Corporation (Diasorin SPA)
- F Hoffmann-La Roche Ltd
- Eurofins Scientific
- 23andMe Inc
- Abbott Laboratories
- Blueprint Genetics Oy
- Danaher Corporation
- Qiagen
- Illumina Inc
- Centogene AG
- Thermo Fisher Scientific
Key Milestones in European DNA Testing Industry Industry
- October 2022: NHS England launches a national genetic testing service, expanding access to rapid life-saving checks for children and babies.
- August 2022: Myriad Genetics partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc, expanding access to genetic testing in Germany and France.
Strategic Outlook for European DNA Testing Industry Market
The European DNA testing market is poised for significant growth over the forecast period. Continued technological innovation, increasing awareness of genetic diseases, and favorable regulatory environments will drive market expansion. Strategic partnerships and market expansion into underserved regions will be crucial for companies to capitalize on emerging opportunities and maintain a competitive edge. The focus on personalized medicine and proactive healthcare will further fuel demand for accurate, accessible, and affordable DNA testing services.
European DNA Testing Industry Segmentation
-
1. Type
- 1.1. Carrier Testing
- 1.2. Diagnostic Testing
- 1.3. Newborn Screening
- 1.4. Predictive and Presymptomatic Testing
- 1.5. Prenatal Testing
- 1.6. Other Types
-
2. Disease
- 2.1. Alzheimer's Disease
- 2.2. Cancer
- 2.3. Cystic Fibrosis
- 2.4. Sickle Cell Anemia
- 2.5. Duchenne Muscular Dystrophy
- 2.6. Thalassemia
- 2.7. Huntington's Disease
- 2.8. Other Diseases
-
3. Technology
- 3.1. Cytogenetic Testing
- 3.2. Biochemical Testing
- 3.3. Molecular Testing
European DNA Testing Industry Segmentation By Geography
- 1. Germany
- 2. United Kingdom
- 3. France
- 4. Italy
- 5. Spain
- 6. Rest of Europe
European DNA Testing Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 10.55% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Emphasis on Early Disease Detection and Prevention; Increasing Demand for Personalized Medicine; Increasing Application of Genetic Testing in Oncology
- 3.3. Market Restrains
- 3.3.1. High Costs of Genetic Testing; Social and Ethical Implications of Genetic Testing
- 3.4. Market Trends
- 3.4.1. The Diagnostic Testing Segment is Expected to Hold a Significant Share Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Carrier Testing
- 5.1.2. Diagnostic Testing
- 5.1.3. Newborn Screening
- 5.1.4. Predictive and Presymptomatic Testing
- 5.1.5. Prenatal Testing
- 5.1.6. Other Types
- 5.2. Market Analysis, Insights and Forecast - by Disease
- 5.2.1. Alzheimer's Disease
- 5.2.2. Cancer
- 5.2.3. Cystic Fibrosis
- 5.2.4. Sickle Cell Anemia
- 5.2.5. Duchenne Muscular Dystrophy
- 5.2.6. Thalassemia
- 5.2.7. Huntington's Disease
- 5.2.8. Other Diseases
- 5.3. Market Analysis, Insights and Forecast - by Technology
- 5.3.1. Cytogenetic Testing
- 5.3.2. Biochemical Testing
- 5.3.3. Molecular Testing
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. Germany
- 5.4.2. United Kingdom
- 5.4.3. France
- 5.4.4. Italy
- 5.4.5. Spain
- 5.4.6. Rest of Europe
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. Germany European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Type
- 6.1.1. Carrier Testing
- 6.1.2. Diagnostic Testing
- 6.1.3. Newborn Screening
- 6.1.4. Predictive and Presymptomatic Testing
- 6.1.5. Prenatal Testing
- 6.1.6. Other Types
- 6.2. Market Analysis, Insights and Forecast - by Disease
- 6.2.1. Alzheimer's Disease
- 6.2.2. Cancer
- 6.2.3. Cystic Fibrosis
- 6.2.4. Sickle Cell Anemia
- 6.2.5. Duchenne Muscular Dystrophy
- 6.2.6. Thalassemia
- 6.2.7. Huntington's Disease
- 6.2.8. Other Diseases
- 6.3. Market Analysis, Insights and Forecast - by Technology
- 6.3.1. Cytogenetic Testing
- 6.3.2. Biochemical Testing
- 6.3.3. Molecular Testing
- 6.1. Market Analysis, Insights and Forecast - by Type
- 7. United Kingdom European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Type
- 7.1.1. Carrier Testing
- 7.1.2. Diagnostic Testing
- 7.1.3. Newborn Screening
- 7.1.4. Predictive and Presymptomatic Testing
- 7.1.5. Prenatal Testing
- 7.1.6. Other Types
- 7.2. Market Analysis, Insights and Forecast - by Disease
- 7.2.1. Alzheimer's Disease
- 7.2.2. Cancer
- 7.2.3. Cystic Fibrosis
- 7.2.4. Sickle Cell Anemia
- 7.2.5. Duchenne Muscular Dystrophy
- 7.2.6. Thalassemia
- 7.2.7. Huntington's Disease
- 7.2.8. Other Diseases
- 7.3. Market Analysis, Insights and Forecast - by Technology
- 7.3.1. Cytogenetic Testing
- 7.3.2. Biochemical Testing
- 7.3.3. Molecular Testing
- 7.1. Market Analysis, Insights and Forecast - by Type
- 8. France European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Type
- 8.1.1. Carrier Testing
- 8.1.2. Diagnostic Testing
- 8.1.3. Newborn Screening
- 8.1.4. Predictive and Presymptomatic Testing
- 8.1.5. Prenatal Testing
- 8.1.6. Other Types
- 8.2. Market Analysis, Insights and Forecast - by Disease
- 8.2.1. Alzheimer's Disease
- 8.2.2. Cancer
- 8.2.3. Cystic Fibrosis
- 8.2.4. Sickle Cell Anemia
- 8.2.5. Duchenne Muscular Dystrophy
- 8.2.6. Thalassemia
- 8.2.7. Huntington's Disease
- 8.2.8. Other Diseases
- 8.3. Market Analysis, Insights and Forecast - by Technology
- 8.3.1. Cytogenetic Testing
- 8.3.2. Biochemical Testing
- 8.3.3. Molecular Testing
- 8.1. Market Analysis, Insights and Forecast - by Type
- 9. Italy European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Type
- 9.1.1. Carrier Testing
- 9.1.2. Diagnostic Testing
- 9.1.3. Newborn Screening
- 9.1.4. Predictive and Presymptomatic Testing
- 9.1.5. Prenatal Testing
- 9.1.6. Other Types
- 9.2. Market Analysis, Insights and Forecast - by Disease
- 9.2.1. Alzheimer's Disease
- 9.2.2. Cancer
- 9.2.3. Cystic Fibrosis
- 9.2.4. Sickle Cell Anemia
- 9.2.5. Duchenne Muscular Dystrophy
- 9.2.6. Thalassemia
- 9.2.7. Huntington's Disease
- 9.2.8. Other Diseases
- 9.3. Market Analysis, Insights and Forecast - by Technology
- 9.3.1. Cytogenetic Testing
- 9.3.2. Biochemical Testing
- 9.3.3. Molecular Testing
- 9.1. Market Analysis, Insights and Forecast - by Type
- 10. Spain European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Type
- 10.1.1. Carrier Testing
- 10.1.2. Diagnostic Testing
- 10.1.3. Newborn Screening
- 10.1.4. Predictive and Presymptomatic Testing
- 10.1.5. Prenatal Testing
- 10.1.6. Other Types
- 10.2. Market Analysis, Insights and Forecast - by Disease
- 10.2.1. Alzheimer's Disease
- 10.2.2. Cancer
- 10.2.3. Cystic Fibrosis
- 10.2.4. Sickle Cell Anemia
- 10.2.5. Duchenne Muscular Dystrophy
- 10.2.6. Thalassemia
- 10.2.7. Huntington's Disease
- 10.2.8. Other Diseases
- 10.3. Market Analysis, Insights and Forecast - by Technology
- 10.3.1. Cytogenetic Testing
- 10.3.2. Biochemical Testing
- 10.3.3. Molecular Testing
- 10.1. Market Analysis, Insights and Forecast - by Type
- 11. Rest of Europe European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - by Type
- 11.1.1. Carrier Testing
- 11.1.2. Diagnostic Testing
- 11.1.3. Newborn Screening
- 11.1.4. Predictive and Presymptomatic Testing
- 11.1.5. Prenatal Testing
- 11.1.6. Other Types
- 11.2. Market Analysis, Insights and Forecast - by Disease
- 11.2.1. Alzheimer's Disease
- 11.2.2. Cancer
- 11.2.3. Cystic Fibrosis
- 11.2.4. Sickle Cell Anemia
- 11.2.5. Duchenne Muscular Dystrophy
- 11.2.6. Thalassemia
- 11.2.7. Huntington's Disease
- 11.2.8. Other Diseases
- 11.3. Market Analysis, Insights and Forecast - by Technology
- 11.3.1. Cytogenetic Testing
- 11.3.2. Biochemical Testing
- 11.3.3. Molecular Testing
- 11.1. Market Analysis, Insights and Forecast - by Type
- 12. Germany European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 13. France European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 14. Italy European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 15. United Kingdom European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 16. Netherlands European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 17. Sweden European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 18. Rest of Europe European DNA Testing Industry Analysis, Insights and Forecast, 2019-2031
- 19. Competitive Analysis
- 19.1. Market Share Analysis 2024
- 19.2. Company Profiles
- 19.2.1 Myriad Genetics Inc
- 19.2.1.1. Overview
- 19.2.1.2. Products
- 19.2.1.3. SWOT Analysis
- 19.2.1.4. Recent Developments
- 19.2.1.5. Financials (Based on Availability)
- 19.2.2 Elitech Group
- 19.2.2.1. Overview
- 19.2.2.2. Products
- 19.2.2.3. SWOT Analysis
- 19.2.2.4. Recent Developments
- 19.2.2.5. Financials (Based on Availability)
- 19.2.3 Luminex Corporation (Diasorin SPA)
- 19.2.3.1. Overview
- 19.2.3.2. Products
- 19.2.3.3. SWOT Analysis
- 19.2.3.4. Recent Developments
- 19.2.3.5. Financials (Based on Availability)
- 19.2.4 F Hoffmann-La Roche Ltd
- 19.2.4.1. Overview
- 19.2.4.2. Products
- 19.2.4.3. SWOT Analysis
- 19.2.4.4. Recent Developments
- 19.2.4.5. Financials (Based on Availability)
- 19.2.5 Eurofins Scientific
- 19.2.5.1. Overview
- 19.2.5.2. Products
- 19.2.5.3. SWOT Analysis
- 19.2.5.4. Recent Developments
- 19.2.5.5. Financials (Based on Availability)
- 19.2.6 F Hoffmann-La Roche Ltd*List Not Exhaustive
- 19.2.6.1. Overview
- 19.2.6.2. Products
- 19.2.6.3. SWOT Analysis
- 19.2.6.4. Recent Developments
- 19.2.6.5. Financials (Based on Availability)
- 19.2.7 23andMe Inc
- 19.2.7.1. Overview
- 19.2.7.2. Products
- 19.2.7.3. SWOT Analysis
- 19.2.7.4. Recent Developments
- 19.2.7.5. Financials (Based on Availability)
- 19.2.8 Abbott Laboratories
- 19.2.8.1. Overview
- 19.2.8.2. Products
- 19.2.8.3. SWOT Analysis
- 19.2.8.4. Recent Developments
- 19.2.8.5. Financials (Based on Availability)
- 19.2.9 Blueprint Genetics Oy
- 19.2.9.1. Overview
- 19.2.9.2. Products
- 19.2.9.3. SWOT Analysis
- 19.2.9.4. Recent Developments
- 19.2.9.5. Financials (Based on Availability)
- 19.2.10 Danaher Corporation
- 19.2.10.1. Overview
- 19.2.10.2. Products
- 19.2.10.3. SWOT Analysis
- 19.2.10.4. Recent Developments
- 19.2.10.5. Financials (Based on Availability)
- 19.2.11 Qiagen
- 19.2.11.1. Overview
- 19.2.11.2. Products
- 19.2.11.3. SWOT Analysis
- 19.2.11.4. Recent Developments
- 19.2.11.5. Financials (Based on Availability)
- 19.2.12 Illumina Inc
- 19.2.12.1. Overview
- 19.2.12.2. Products
- 19.2.12.3. SWOT Analysis
- 19.2.12.4. Recent Developments
- 19.2.12.5. Financials (Based on Availability)
- 19.2.13 Centogene AG
- 19.2.13.1. Overview
- 19.2.13.2. Products
- 19.2.13.3. SWOT Analysis
- 19.2.13.4. Recent Developments
- 19.2.13.5. Financials (Based on Availability)
- 19.2.14 Thermo Fisher Scientific
- 19.2.14.1. Overview
- 19.2.14.2. Products
- 19.2.14.3. SWOT Analysis
- 19.2.14.4. Recent Developments
- 19.2.14.5. Financials (Based on Availability)
- 19.2.1 Myriad Genetics Inc
List of Figures
- Figure 1: European DNA Testing Industry Revenue Breakdown (Million, %) by Product 2024 & 2032
- Figure 2: European DNA Testing Industry Share (%) by Company 2024
List of Tables
- Table 1: European DNA Testing Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 2: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 3: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 4: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 5: European DNA Testing Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 6: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 7: Germany European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 8: France European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: Italy European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 10: United Kingdom European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 11: Netherlands European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: Sweden European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: Rest of Europe European DNA Testing Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 15: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 16: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 17: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 18: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 19: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 20: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 21: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 22: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 23: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 24: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 25: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 26: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 27: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 28: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 29: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 30: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 31: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 32: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 33: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 34: European DNA Testing Industry Revenue Million Forecast, by Type 2019 & 2032
- Table 35: European DNA Testing Industry Revenue Million Forecast, by Disease 2019 & 2032
- Table 36: European DNA Testing Industry Revenue Million Forecast, by Technology 2019 & 2032
- Table 37: European DNA Testing Industry Revenue Million Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the European DNA Testing Industry?
The projected CAGR is approximately 10.55%.
2. Which companies are prominent players in the European DNA Testing Industry?
Key companies in the market include Myriad Genetics Inc, Elitech Group, Luminex Corporation (Diasorin SPA), F Hoffmann-La Roche Ltd, Eurofins Scientific, F Hoffmann-La Roche Ltd*List Not Exhaustive, 23andMe Inc, Abbott Laboratories, Blueprint Genetics Oy, Danaher Corporation, Qiagen, Illumina Inc, Centogene AG, Thermo Fisher Scientific.
3. What are the main segments of the European DNA Testing Industry?
The market segments include Type, Disease, Technology.
4. Can you provide details about the market size?
The market size is estimated to be USD 6.17 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Emphasis on Early Disease Detection and Prevention; Increasing Demand for Personalized Medicine; Increasing Application of Genetic Testing in Oncology.
6. What are the notable trends driving market growth?
The Diagnostic Testing Segment is Expected to Hold a Significant Share Over the Forecast Period.
7. Are there any restraints impacting market growth?
High Costs of Genetic Testing; Social and Ethical Implications of Genetic Testing.
8. Can you provide examples of recent developments in the market?
October 2022: NHS England launched a national genetic testing service to deliver rapid life-saving checks for children and babies. As a result of the launch, patients can undergo simple blood tests. Once they are processed, the service is likely to give medical teams from across the country results within days, meaning they can kick-start lifesaving treatment plans for more than 6,000 genetic diseases.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "European DNA Testing Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the European DNA Testing Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the European DNA Testing Industry?
To stay informed about further developments, trends, and reports in the European DNA Testing Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
